InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update
12 mai 2022 07h30 HE
|
InflaRx N.V.
Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities...
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
31 mars 2022 07h30 HE
|
InflaRx N.V.
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary...
InflaRx Reports Full Year 2021 Financial and Operating Results
24 mars 2022 07h30 HE
|
InflaRx N.V.
Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativaPositive Phase IIa data reported with vilobelimab in pyoderma gangrenosum; data being...
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
17 mars 2022 07h30 HE
|
InflaRx N.V.
JENA, Germany, March 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
08 mars 2022 07h30 HE
|
InflaRx N.V.
JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
28 févr. 2022 07h30 HE
|
InflaRx N.V.
JENA, Germany, Feb. 28, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
16 févr. 2022 07h30 HE
|
InflaRx N.V.
In vilobelimab and pembrolizumab combination arm, the three patients enrolled in the first dosing cohort have been treated for 36 days with no safety concernsSteering Committee unanimously voted to...
InflaRx to Present at Annual SVB Leerink Global Health Conference
08 févr. 2022 07h30 HE
|
InflaRx N.V.
JENA, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
10 janv. 2022 07h30 HE
|
InflaRx N.V.
Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:...
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events
05 janv. 2022 08h00 HE
|
InflaRx N.V.
Presentation at J.P. Morgan Healthcare Conference on January 13thCorporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10thCompany to host virtual R&D...